GSK Says Boehringer Spreading Lies About Its Inhalers
By Hailey Konnath (November 13, 2019, 9:09 PM EST) -- Pharmaceutical company GlaxoSmithKline LLC on Tuesday accused rival Boehringer Ingelheim Pharmaceuticals Inc. of spreading false and misleading information about GSK inhalers for patients with chronic obstructive pulmonary disease, according to a suit filed in Pennsylvania federal court.
Boehringer Ingelheim is downplaying the effectiveness of GSK's Ellipta and Diskus inhalers while promoting its own inhaler to medical providers, GSK said in its complaint.
"[Boehringer Ingelheim's] message is belied by overwhelming critical evidence," GSK said. "Nevertheless, BI has refused to make any further changes to its marketing campaign and has continued to make false and misleading statements about GSK's products."
According to the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!